TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

ARROWHEAD

Infectious DiseaseCardiovascularRespiratory
Pharma

ARROWHEAD is a pharmaceutical company focused on Infectious Disease, Cardiovascular, Respiratory. Key products include REDEMPLO.

2025
Since
1
Drugs
-
Trials
1
Approved (2yr)

Key Drugs

REDEMPLO
plozasiran sodium
ApoC-III mRNA 1 indications · 2025

Recent Activity

REDEMPLO 2025-11-18
Type 1 - New Molecular Entity
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 47%
0 drugs Phase 2: 6 Phase 1: 3
Cardiovascular 22%
0 drugs Phase 3: 1 Phase 2: 1 Phase 1: 1
Respiratory 22%
0 drugs Phase 2: 1 Phase 1: 5
Metabolic 6%
0 drugs Phase 1: 2
Neurology 3%
0 drugs Phase 1: 1

Pipeline Strength Pro

Loading...

Competitors Pro

GE HEALTHCARE specialty
Infectious Disease, Neurology, Cardiovascular, Respiratory
Merck big-pharma
Infectious Disease, Cardiovascular, Metabolic
Novo Nordisk big-pharma
Metabolic, Cardiovascular, Infectious Disease, Neurology
LEDERLE big-pharma
Infectious Disease, Cardiovascular, Neurology, Respiratory
Johnson & Johnson big-pharma
Infectious Disease, Cardiovascular, Metabolic